Key clinical point: Eluxadoline is effective for a broad range of symptoms of irritable bowel syndrome with diarrhea in patients who didn’t respond to loperamide.

Major finding: Eluxadoline was more than twice as effective as placebo at improving global symptoms of irritable bowel syndrome with diarrhea in patients who had failed to respond adequately to loperamide.

Study details: This was a randomized, double-blind, multicenter, phase 4, placebo-controlled trial including 346 patients with moderate to severe irritable bowel syndrome with diarrhea.

Disclosures: The presenter reported serving as a consultant to and speaker for Allergan, which markets eluxadoline and sponsored the RELIEF trial.